- Home
- GXAI vs THAR Comparison
GXAI vs THAR Comparison
Compare GXAI & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- THAR
- Stock Information
- Founded
- GXAI 2021
- THAR 2017
- Country
- GXAI United States
- THAR United States
- Employees
- GXAI N/A
- THAR N/A
- Industry
- GXAI
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- GXAI
- THAR Health Care
- Exchange
- GXAI Nasdaq
- THAR Nasdaq
- Market Cap
- GXAI 19.7M
- THAR 16.8M
- IPO Year
- GXAI 2023
- THAR 2022
- Fundamental
- Price
- GXAI $1.61
- THAR $2.94
- Analyst Decision
- GXAI
- THAR Strong Buy
- Analyst Count
- GXAI 0
- THAR 1
- Target Price
- GXAI N/A
- THAR $17.00
- AVG Volume (30 Days)
- GXAI 15.2M
- THAR 29.4M
- Earning Date
- GXAI 11-13-2025
- THAR 11-06-2025
- Dividend Yield
- GXAI N/A
- THAR N/A
- EPS Growth
- GXAI N/A
- THAR N/A
- EPS
- GXAI N/A
- THAR N/A
- Revenue
- GXAI $198,711.00
- THAR N/A
- Revenue This Year
- GXAI N/A
- THAR N/A
- Revenue Next Year
- GXAI N/A
- THAR N/A
- P/E Ratio
- GXAI N/A
- THAR N/A
- Revenue Growth
- GXAI 72158.55
- THAR N/A
- 52 Week Low
- GXAI $1.00
- THAR $0.95
- 52 Week High
- GXAI $7.50
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- GXAI 50.57
- THAR 46.57
- Support Level
- GXAI $1.41
- THAR $2.75
- Resistance Level
- GXAI $1.85
- THAR $3.46
- Average True Range (ATR)
- GXAI 0.18
- THAR 0.96
- MACD
- GXAI -0.03
- THAR -0.31
- Stochastic Oscillator
- GXAI 21.51
- THAR 3.58
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.